Price (delayed)
$5.49
Market cap
$793.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.32
Enterprise value
$721.09M
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by
There are no recent dividends present for ALLO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.